Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185
Repligen Corporation
Repligen Corporation RGEN | 0.00 |
Wells Fargo analyst Evan Stampler maintains Repligen (NASDAQ:
RGEN) with a Overweight and raises the price target from $180 to $185.